Smooth Drug Development September 2026 News Release
News – September 2026
Clinical and Scientific Departments News:
Phase I-IV Clinical Trials
• A Phase III Dermatology Study: Recruitment update: 6 sites have been opened, 7 subjects have been screened, and 2 have been randomized. Enrollment continues as planned.
• A Phase I Hodgkin lymphoma Study: A total of 10 subjects have been screened, and 9 have been randomized. A total of 10 subjects were screened, and 9 were randomized.
• A Phase I Locally advanced or metastatic non-small cell lung cancer (NSCLC) Study: A total of 26 subjects has been screened, and 23 have been randomized.
• A Phase III Infectious Disease Study: Regulatory approval has been received in Georgia, and the first 20 patients have been screened in Pakistan.
• A Phase III Gynecology Study I: Subject recruitment for the study has been completed, with 204 patients having been randomized.
• A Phase III Gynecology study II: A total of 160 patients has been randomized.
• A Phase III Gynecology study III: The first subject has been screened.
Bioequivalence (BE) Study
• Acalabrutinib BE study in healthy volunteers: All 58 subjects were randomized, and 57 successfully completed the study.
Business Development News:
Our Business Development team has been actively expanding partnerships and exploring new opportunities through strategic discussions and conference participation.
Key Partner Engagements
• The Smooth Drug Development Business Development team will attend CPHI Milan 2026 from 6–8 October 2026 at Fiera Milano, Italy.
• The business development team of Smooth Drug Development will also attend World Vaccine Congress Europe 2026 from 19–21October 2026 at the RAI Convention Centre, Amsterdam.